Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Orlistat, sold under the brand name Xenical among others, is a medication used to treat obesity. Its primary function is preventing the absorption of fats from the human diet by acting as a lipase inhibitor, thereby reducing caloric intake. It is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet.
Read the full article on WikipediaObesity Clinical criteria: Treatment Phase: Initial treatment Patient must have a Body Mass Index (BMI) greater than or equal to 35 with no known co-morbidities; OR Patient must have a BMI greater than or equal to 30 with 1 or more of the following co-morbidities;(i) diabetes;(ii) ischaemic heart disease;(iii) psychiatric conditions;(iv) hypertension, AND Patient must be receiving, or enrolled to receive, professional dietetic and weight management advice (where this is available), AND The treatment must not exceed 12 months in total from initial application, AND Patient must not receive more than 1 continuous treatment in a lifetime. The prescriber must provide the patient's initial body weight and BMI at the time of application.
“Orlistat works by inhibiting gastric and pancreatic lipases, the enzymes that break down triglycerides in the intestine. When lipase activity is blocked, triglycerides from the diet are not hydrolyzed into absorbable free fatty acids, and instead are excreted unchanged. Only trace amounts of orlistat are absorbed systemically; the primary effect is local lipase inhibition within the GI tract after an oral dose. The primary route of elimination is through the feces.”
“1 to 2 hours”
Working under the parallel aged-care framework? Aged-care equivalent →